Volume 60, Issue 4 pp. 593-598
Research Article

Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma

Surya Rednam MD

Corresponding Author

Surya Rednam MD

Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas

Texas Children's Hospital, 6701 Fannin St., CC1510.06, Houston, TX 77030.===Search for more papers by this author
Michael E. Scheurer PhD, MPH

Michael E. Scheurer PhD, MPH

Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas

Search for more papers by this author
Adekunle Adesina MD, PhD

Adekunle Adesina MD, PhD

Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas

Search for more papers by this author
Ching C. Lau MD, PhD

Ching C. Lau MD, PhD

Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas

Search for more papers by this author
Mehmet Fatih Okcu MD, MPH

Mehmet Fatih Okcu MD, MPH

Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas

Search for more papers by this author
First published: 12 October 2012
Citations: 46

Conflict of interest: Nothing to declare.

Abstract

Background

Glutathione S-transferase (GST) enzymes are involved in detoxifying chemotherapy and clearing reactive oxygen species formed by radiation. We explored the relationship between the host GSTP1 105 A > G polymorphism (rs1695), tumor GSTpi protein expression, and clinical outcomes in pediatric medulloblastoma. We hypothesized that the GSTP1 105 G-allele and increased tumor GSTpi expression would be associated with lower progression-free survival and fewer adverse events.

Procedure

The study included 106 medulloblastoma/primitive neuroectodermal tumor (PNET) patients seen at Texas Children's Cancer Center. Genotyping was performed using an Illumina HumanOmni1-Quad BeadChip and GSTpi expression was assessed using immunohistochemistry. We used the Kaplan–Meier method for survival analyses and logistic regression for toxicity comparisons.

Results

Patients with a GSTP1 105 AG/GG genotype (vs. AA) or who had received high dose craniospinal radiation (≥34 Gy vs. <26 Gy) had a greater risk of requiring hearing aids than their counterparts (OR 4.0, 95% CI 1.2–13.6, and OR 3.1, 95% CI 1.1–8.8, respectively, n = 69). Additionally, there was a statistically significant interaction between these variables. Compared with the lowest risk group (GSTP1 105 AA–low dose radiation), patients with a GSTP1 105 AG/GG genotype who received high dose radiation were 8.4 times more likely to require hearing aids (95% CI 1.4–49.9, p-trend = 0.005, n = 69). When adjusted for age, cumulative cisplatin dose, and amifostine use, the association remained.

Conclusions

The GSTP1 105 G-allele is associated with permanent ototoxicity in pediatric medulloblastoma/PNET and strongly interacts with radiation dose. Patients with this allele should be considered for clinical trials employing radiation dose modifications and cytoprotectant strategies. Pediatr Blood Cancer 2013; 60: 593–598. © 2012 Wiley Periodicals, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.